ERBB2 and breast cancer: However, in breast cancer, it has been reported that PDPN(+) CAFs can diverge into protumorigenic CAFs during tumor progression,31 or promote resistance to trastuzumab in HER2+ cancer by secreting immunosuppressive factors.30